CEACAM5 and non-small cell lung carcinoma: The ADC’s design leverages CEACAM5’s tumour-restricted expression pattern (minimal in normal tissues) to maximise therapeutic index while minimising off-target toxicity—a critical advantage in treating advanced NSCLC where conventional chemotherapy often shows limited efficacy and significant adverse effects [31].